Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Dabur India Limited is a major FMCG company in India, renowned for its diverse range of herbal and Ayurvedic products. It operates across segments including Hair Care, Oral Care, Health Care, Skin Care, Home Care, and Foods.
Recently, Dabur India reported an impressive doubling in growth in key product categories such as Amla hair oils, Dabur Red Toothpaste, and its premium Coconut Milk and Edible Oil range, showcasing the company's ability to innovate and capture market share.
Dabur focuses on strategic partnerships and global expansions. It entered an alliance with Amazon, strengthening its U.S. and international market presence. This strategy complements its robust domestic distribution network and wide product reach.
Significant achievements include a strong market share in hair oils and oral care, demonstrating superior growth above industry averages, bolstered by intensive advertising and innovative product lines.
Despite challenges with geopolitical disturbances affecting exports, Dabur consistently achieves robust financial outcomes, with notable Q3 FY26 growth in revenue and profit margins, signaling sustained fiscal health and robust operational performance.
Personal Products
Personal Care
74,896 Cr
Low Risk
39.5
42.9
2.9
6.6
576.80
401.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Dabur India Ltd (DABUR) is currently trading at 426.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dabur India Limited is a major FMCG company in India, renowned for its diverse range of herbal and Ayurvedic products. It operates across segments including Hair Care, Oral Care, Health Care, Skin Care, Home Care, and Foods. Recently, Dabur India reported an impressive doubling in growth in key product categories such as Amla hair oils, Dabur Red Toothpaste, and its premium Coconut Milk and Edible Oil range, showcasing the company's ability to innovate and capture market share. Dabur focuses on strategic partnerships and global expansions. It entered an alliance with Amazon, strengthening its U.S. and international market presence. This strategy complements its robust domestic distribution network and wide product reach. Significant achievements include a strong market share in hair oils and oral care, demonstrating superior growth above industry averages, bolstered by intensive advertising and innovative product lines. Despite challenges with geopolitical disturbances affecting exports, Dabur consistently achieves robust financial outcomes, with notable Q3 FY26 growth in revenue and profit margins, signaling sustained fiscal health and robust operational performance.
Over the past 52 weeks, Dabur India Ltd has traded between a low of ₹401.05 and a high of ₹576.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dabur India Ltd has a market capitalization of approximately 74,896.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dabur India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 39.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 74,896.27 Cr, Dabur India Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dabur India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dabur India Ltd is 39.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Dabur said the USFDA issued Import Alert 66-40 covering drugs made at a small section of its Silvassa facility after inspection findings on data integrity and maintenance.
Dabur said the FDA action followed an inspection that flagged data integrity and maintenance lapses, along with record-keeping concerns at the Silvassa plant in Dadra and Nagar Haveli.
Dabur India acquired a 51% equity stake in Badshah Masala, making it a subsidiary of Dabur.
The High Court dismissed Dabur’s appeal and upheld an interim injunction restraining Dabur from selling “Cool King Thanda Tael” in the impugned trade dress found deceptively similar to Emami’s Navratna packaging.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockBearish
5
Neutral
7
Bullish
2
Bearish
28
Neutral
7
Bullish
11
Bearish
23
Neutral
0
Bullish
9
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1036.80 | 1,03,184 Cr | 55.43 | 8.15 | 1.98 | 14.71 | 17.09 | 8.73 | ||
426.70 | 74,896 Cr | 39.52 | 6.56 | 1.95 | 16.59 | 20.18 | 10.69 | ||
2080.00 | 55,178 Cr | 41.63 | 34.83 | 2.37 | 83.66 | 109.56 | 38.89 | ||
9010.00 | 29,308 Cr | 34.22 | 38.90 | 2.82 | 113.67 | 155.91 | 47.49 | ||
7712.60 | 24,961 Cr | 38.15 | 26.37 | 0.78 | 69.13 | 94.29 | 34.96 | ||
159.95 | 20,923 Cr | 193.32 | 46.41 | 0.00 | 24.01 | 28.64 | 19.56 | ||
390.95 | 16,884 Cr | 21.78 | 5.77 | 1.55 | 26.51 | 27.65 | 20.21 | ||
| Median: 7 Co. | — | 1036.80 | 29,308 Cr | 39.52 | 26.37 | 1.95 | 26.51 | 28.64 | 20.21 |
Regulatory Import Alert
US FDA issued Import Alert IA-66-40 (June 10, 2026) for drugs manufactured at Dabur's Silvassa plant citing data-integrity and maintenance deficiencies; Dabur says impact is limited, plant remains operational and it is engaging with FDA.
Import Alert
US FDA issued Import Alert (IA 66-40) on June 10, 2026 for drugs manufactured at Dabur's Silvassa plant citing data-integrity and maintenance lapses; Dabur says impact is limited to private-label US products, plant remains operational and it is engaging with FDA.
Scheme of Amalgamation
Dabur published a newspaper notice (dated June 9, 2026) that the NCLT New Delhi will hear the Company Petition for the proposed amalgamation of Sesa Care Pvt Ltd into Dabur on August 3, 2026 (petition filed May 14, 2026).
Amalgamation notice
Dabur published a newspaper notice (June 9, 2026) that the NCLT will hear the company petition on Aug 3, 2026 (per NCLT order dated May 25, 2026) for the proposed Scheme of Amalgamation between Sesa Care Pvt Ltd and Dabur India Ltd.
